Faber Daeufer Itrato & Cabot’s clients are public and private companies, not-for-profit research and educational institutions, hospitals and venture, angel and private equity investors. We provide counsel in corporate and commercial matters, and handle transactions including entity formation, financing, technology licensing, discovery/development collaborations, product/program alliances or joint ventures, and private M&A transactions. We are committed to delivering legal services in a pragmatic manner that optimizes efficiency and effectiveness.
Click here to read the National Law Journals' Small Firm Spotlight article on the Firm
Corporate and Venture Capital
Faber Daeufer Itrato & Cabot’s lawyers serve as corporate counsel for many private biotechnology and high technology companies – ranging from private biotechnology companies like Lux Biosciences, which has filed for approval in the United States and Europe for its first pharmaceutical product, to emerging technology companies like Equity Solar, PV Tech Group, Juliet Marine Systems and Caisson. We advise management and boards of directors, from a legal perspective, about financing, strategic transactions, governance, equity compensation plans and compliance.
From a transactional perspective, we handle the full range of financing transactions for private companies, including angel investments, early and follow-on rounds of equity financing, venture debt, conventional bank debt, equipment financing and capital leasing. We have been actively involved in the preparation of model documents published by the National Venture Capital Association, and we have developed strong working relationships with most of the traditional venture capital firms, corporate venture affiliates, banks and angel groups who are active and substantial players in life sciences and emerging technology financing in the United States.
We regularly handle mergers, acquisitions, dispositions, joint ventures and spin-outs, and strategic investment in securities of research and development collaborators. Our experience has included some of the largest M&A transactions in the life sciences industry in the past few years, as well as strategically important acquisitions from distressed sales.
We also advise clients concerning real estate leasing, equity compensation plans, securities law compliance, public disclosure and corporate governance, board administration and general corporate counsel.
Licensing and Collaborations for Development and Commercialization
The Firm's licensing and collaboration practice in the life sciences is among the deepest and most comprehensive in the country.
In general, the Firm's professionals handle:
- technology platform licensing
- drug target and product candidate alliances
- FTO licensing
- disclosure of confidential information and material transfer
- product research, development and commercialization collaborations
- supply chain contracting and licensing
- exclusive and non-exclusive distribution arrangements
- promotion and co-promotion arrangements
- "day-to-day" contracting for evaluations, licenses, sponsored research, clinical trials, manufacturing and consulting
- customized form agreement preparation, staff training and contracts management
For almost any transaction that a client may contemplate, we can staff that transaction with senior lawyers and/or contracts specialists who focus their practices on handling exactly that kind of transaction. And, when potential clients ask for “deal sheets,” we can usually provide multiple recent examples not just of the general category of transaction (for example, “a development and license agreement”) but also of the specific transaction the client is contemplating (for example, “a cross-border indication split for a small molecule where worldwide supply will be controlled by the IP holder”). In many cases, we will also have recent experience sitting across the table from the potential counterparty.
Faber Daeufer Itrato & Cabot's life sciences expertise translates readily to other emerging technology sectors, where our principals have led licensing and collaboration transactions in fields such as solar energy, semiconductors and software.